EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Protective Function Of Ceruloplasmin And Its Action On Erythrocytes In Men With Prostate Tumors

Nanuli Kotrikadze, Mikheil Zibzibadze, Liana Ramishvili, Teimuraz Chigogidze, Lavrenti Managadze

European Medical, Health and Pharmaceutical Journal · 2011

DOI: 10.12955/emhpj.v2i0.335 ↗
AbstractBibliografische Angaben

Abstract

Purpose: To investigate the protective action of Ceruloplasmin (Cp) on the lysis of erythrocytes in men with prostate tumors. Material and Methods: The blood erythrocytes of the patients with benign hyperplasia of prostate (BHP) and prostate adenocarcinoma (CaP) were studied. Patients at the age 60-75 with early stages of a cancer have been investigated. The control group was consisted of apparently healthy males with the compatible age. n=15 for each group. The clinical stage of the disease was diagnosed by means of rectal, histological and echographic examination of the prostate gland. Photometric methods were applied to register lysis dynamics in order to test out the protective action of Cp. Results: The nonspecific protective function of Cp preparation on BHP and CaP erythrocytes as well as on the control group erythrocytes was revealed. CaP erythrocytes have shown more sensitivity to the lysis provocative factor than BHP and the control group erythrocytes, that was presumably attributed to the structural and functional changes of the erythrocytes developed in the presence of malignant tumor.Conclusion: The results show the importance of Ceruloplasmin as bioantioxidant and support the possibility of its use for therapeutic purposes, for example, in the complex course of treatment for prostate cancer.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →